Choose a language and wait for the translated text.
The deal follows positive mid-stage results for Gilead's experimental pill for chronic bowel disease, emvistegrast, on Monday and adds the new inflammatory bowel disease candidate to its portfolio.
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal | PharmaVoice
